Mortality in Asian Indians with Charcot’s neuroarthropathy: a nested cohort prospective study

  • Shakun Chaudhary
  • Anil Bhansali
  • Ashu RastogiEmail author
Original Article



We studied mortality in individuals of diabetes with or without Charcot neuroarthropathy (CN).


People attending diabetic foot care facility with CN of foot (Cohort 1) were prospectively evaluated. Details pertaining to the duration of diabetes, microvascular and macrovascular complications, foot ulcer, amputation and mortality outcomes were recorded and compared with those without foot complications (Cohort 2) by multivariate logistic regression.


Data for 260 individuals of diabetes with CN and 520 individuals without CN were analysed. Mean age at presentation with CN was 55.8 ± 9.1 years, and duration of diabetes was 12.9 ± 7.8 years. 39.8% individuals with CN had foot ulcer, and 15.3% had amputation. People with CN were younger (55 ± 9.1 vs. 59.9 ± 8.1 years, p < 0.001) and had higher prevalence of microvascular complications. A total of 39 (15%) individuals with CN and 50 (9.8%) (p = 0.03) individuals without CN died during median follow-up of 40(24–51) months. People with CN had 2.7 times (OR 2.72, 95% CI 1.4–5.2, p = 0.003) increased mortality risk when matched for potential confounders. Prevalent CAD and low eGFR predicted higher mortality in people with CN.


People with Charcot neuroarthropathy have almost three times increased risk of mortality despite being younger at presentation.


Charcot neuroarthropathy Asian Indians Mortality Amputation Diabetic neuropathy 



We thank Miss Deeksha for data entry.

Author contributions

AR was involved in conceptualising the study, prospective follow-up, clinical care of the patients, writing and editing the manuscript. SC analysed the data and wrote the initial draft of the manuscript. AB conceptualised the study and edited the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by the Institute Ethics Committee.

Informed consent

A written and informed consent was obtained from all the participants of the present study.

Supplementary material

592_2019_1376_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 12 kb)


  1. 1.
    Cho NW, Shaw JE, Karunga S et al (2018) IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138:271–281. CrossRefGoogle Scholar
  2. 2.
    Rastogi A, Prakash M, Bhansali A (2018) Varied presentations and outcomes of Charcot neuroarthropathy in patients with diabetes mellitus. Int J Diabetes Dev Ctries. Google Scholar
  3. 3.
    Frykberg RG, Belczyk R (2008) Epidemiology of the Charcot foot. Clin Podiatr Med Surg 25(1):17–28CrossRefGoogle Scholar
  4. 4.
    Chammas NK, Hill RLR, Edmonds ME (2016) Increased mortality in diabetic foot ulcer patients: the significance of ulcer type. J Diabetes Res 2016:2879809. CrossRefGoogle Scholar
  5. 5.
    Armstrong DG, Todd WF, Lavery LA, Karkless LB, Bushman TR (1997) The natural history of acute Charcot’s arthropathy in a diabetic foot specialty clinic. Diabet Med 14:357–363CrossRefGoogle Scholar
  6. 6.
    Fabrin J, Larsen K, Holstein PE (2000) Long-term follow-up in diabetic Charcot feet with spontaneous onset. Diabetes Care 23:796–800CrossRefGoogle Scholar
  7. 7.
    Gazis A, Pound N, Macfarlane R, Treece K, Game FL, Jeffcoate WJ (2004) Mortality in patients with diabetic neuropathic osteoarthropathy (Charcot foot). Diabet Med 21:1243–1246CrossRefGoogle Scholar
  8. 8.
    Baal JV, Hubbard R, Game F, Jeffcoate W (2010) Mortality associated with acute Charcot foot and neuropathic foot ulceration. Diabetes Care 33:1086–1089CrossRefGoogle Scholar
  9. 9.
    Sohn MW, Lee TA, Stuck RM, Frykberg RG, Mak EB (2009) Mortality risk of Charcot arthropathy compared with that of diabetic foot ulcer and diabetes alone. Diabetes Care 32(5):816–821CrossRefGoogle Scholar
  10. 10.
    Thewjitcharoen Y, Sripatpong J, Parksook W et al (2018) Salient features and outcomes of Charcot foot—an often-overlooked diabetic complication: a 17-year-experience at a diabetic center in Bangkok. J Clin Transl Endocrinol 11:1–6Google Scholar
  11. 11.
    Rastogi A, Bhattacharya A, Prakash M et al (2016) Utility of PET/CT with fluorine-18-fluorodeoxyglucose-labeled autologous leukocytes for diagnosing diabetic foot osteomyelitis in patients with Charcot’s neuroarthropathy. Nucl Med Commun 37:1253–1259CrossRefGoogle Scholar
  12. 12.
    Anichini R, Policardo L, Lombardo FL, Salutini E et al (2017) Hospitalization for Charcot neuroarthropathy in diabetes. Diabetes Res Clin Pract 129:25–31CrossRefGoogle Scholar
  13. 13.
    Seghieri G, Policardo L, Gualdani E, Anichini R, Francesconi P (2019) Gender difference in the risk for cardiovascular events or mortality of patients with diabetic foot syndrome. Acta Diabetol 56:561–567CrossRefGoogle Scholar
  14. 14.
    Bergis D, Bergis PM, Hermanns N, Zink K, Haak T (2014) Coronary artery disease as an independent predictor of survival in patients with type 2 diabetes and Charcot neuro-osteoarthropathy. Acta Diabetol 51:1041–1048CrossRefGoogle Scholar
  15. 15.
    Sohn M-W, Stuck RM, Pinzur M, Lee TA, Budiman-Mak E (2010) Lower-extremity amputation risk after Charcot arthropathy and diabetic foot ulcer. Diabetes Care 33:98–100CrossRefGoogle Scholar
  16. 16.
    Iversen MM, Grethe S, Tell GS et al (2009) History of foot ulcer increases mortality among individuals with diabetes. Diabetes Care 32(12):2193–2199CrossRefGoogle Scholar
  17. 17.
    Sämann A, Pofahl S, Lehmann T et al (2012) Diabetic nephropathy but not HbA1c is predictive for frequent complications of Charcot feet—long-term follow-up of 164 consecutive patients with 195 acute Charcot feet. Exp Clin Endocrinol Diabetes 120(6):335–339CrossRefGoogle Scholar
  18. 18.
    Brownrigg JR, Hughes CO, Burleigh D, Karthikesalingam A et al (2016) Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol 4(7):588–597CrossRefGoogle Scholar
  19. 19.
    Game FL, Catlow R, Jones GR et al (2012) Audit of acute Charcot’s disease in the UK: the CDUK study. Diabetologia 55:32–35CrossRefGoogle Scholar
  20. 20.
    Rastogi A, Prakash M, Bhansali A (2018) Varied presentations and outcome of Charcot neuroarthropathy in patients with diabetes mellitus. Int J Diabetes Dev Ctries. [Ahead of print] Google Scholar
  21. 21.
    Borys S, Ludwig-Slomczynska AH, Seweryn M et al (2019) Negative pressure wound therapy in the treatment of diabetic foot ulcers may be mediated through differential gene expression. Acta Diabetol 56:115–120CrossRefGoogle Scholar
  22. 22.
    Li G, Hopkins RB, Levine MAH, Jin X et al (2017) Relationship between hyperbaric oxygen therapy and quality of life in participants with chronic diabetic foot ulcers: data from a randomized controlled trial. Acta Diabetol 54(9):823–831CrossRefGoogle Scholar
  23. 23.
    Rastogi A, Hajela A, Prakash M et al (2019) Teriparatide [rhPTH(1-34)] increases foot bone remodeling in diabetic chronic Charcot’s neuroarthropathy: a randomized, double blind, placebo-controlled study. J Diabetes. [Epub ahead of print] Google Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of EndocrinologyPGIMERChandigarhIndia

Personalised recommendations